GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Research & Development

Sinco Pharmaceutical Holdings (HKSE:06833) Research & Development : HK$0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Sinco Pharmaceutical Holdings's Research & Development for the six months ended in Jun. 2024 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0 Mil.


Sinco Pharmaceutical Holdings Research & Development Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Research & Development Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sinco Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sinco Pharmaceutical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinco Pharmaceutical Holdings  (HKSE:06833) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Sinco Pharmaceutical Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinco Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
Executives
Huang Zhijian 2305 Beneficiary of a trust
Fullwealth Holdings Limited 2201 Interest of corporation controlled by you
Risun Investments Limited 2101 Beneficial owner
Wickhams Cay Trust Company Limited 2301 Trustee
Huang Xiangbin 2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings Headlines

No Headlines